Ceribell Inc. released an investor presentation outlining its AI-powered point-of-care EEG platform for use in acute care settings, with a focus on seizure management in the ICU and emergency department and plans for broader indication expansion. The company highlighted FY25 revenue of $89.1 million, 36% year-over-year revenue growth and an 88% gross margin, and cited a U.S. market opportunity of $3.5 billion including an adult seizure acute care market estimated at more than $2 billion. The presentation also detailed pediatric and neonate indication expansion, noting FDA clearances in 2025 for its Clarity algorithms for ages 1+ and for neonates including pre-term, and a planned full launch in Q2 2026. Ceribell referenced clinical and economic findings from the SAFER-EEG study, including a reduction in median door-to-EEG time (25.3 hours with conventional EEG vs. 5.9 hours with Ceribell) and a shorter median ICU length of stay (8.0 days vs. 3.9 days). You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ceribell Inc. published the original content used to generate this news brief on March 04, 2026, and is solely responsible for the information contained therein.